The convergence of advanced technologies and advancements in drug delivery is reshaping diabetes care. Digital therapeutics ...

Fintel reports that on January 7, 2025, Citigroup initiated coverage of EyePoint Pharmaceuticals (NasdaqGM:EYPT) with a Buy recommendation. Analyst Price Forecast Suggests 265.47% Upside As of ...

Both HSCR and BBS can significantly impact a child’s quality of life. HSCR can lead to complications such as intestinal ...

Background: Gestational diabetes mellitus (GDM) is a temporary metabolic disorder ... All pregnant women were initially in treatment in the obstetrics department of Quzhou People’s Hospital and then ...

Insurance coverage for intravitreal injections, an essential treatment for diabetic retinopathy, depends on the specific terms and conditions of an individual’s health insurance policy.

The phase 1 clinical trial is a multicenter, open-label, dose-escalation study to assess drug safety via intravitreal ...

Diabetic retinopathy is a serious concern for people dealing with diabetes. Detecting diabetic retinopathy poses significant challenges, requiring skilled professionals, extensive manual image ...

Ip MS. Update on the current treatment of diabetic retinopathy. Presented at: American Academy of Ophthalmology meeting; Oct. 18-21, 2024; Chicago.

Diabetic retinopathy is a common complication in people with type 1 and type 2 diabetes, progressing from mild, moderate, and ...

Valo Health’s Rho kinase (ROCK) 1 and 2 inhibitor has failed to reduce the severity of diabetic retinopathy in a phase 2 trial, leading the Flagship-founded biotech to drop the candidate.